SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, and Navitus Health Solutions, LLC, a pass-through pharmacy benefit manager (PBM) committed to removing cost from the drug supply chain, today announced the launch of Savings Connect.

加利福尼亚州圣莫尼卡（BUSINESS WIRE）-医疗储蓄和信息的领先资源GoodRx（纳斯达克股票代码：GDRX）和致力于消除成本的传递药房福利经理（PBM）Navitus Health Solutions，LLC今天宣布启动储蓄连接。

This program, when elected by clients, provides members with automatic access to GoodRx prices on generic drugs in a seamless experience at the pharmacy counter. Consumers no longer have to proactively review and choose between using their insurance or a discounted price available through GoodRx. Both prices are compared behind the scenes and the lowest one is delivered directly to the consumer..

该计划由客户当选后，可让成员在药房柜台无缝体验中自动访问仿制药的GoodRx价格。消费者不再需要主动审查和选择使用他们的保险或通过GoodRx提供的折扣。这两种价格都是在后台进行比较的，最低的价格直接交付给消费者。。

“We are focused on expanding into the insurance benefit market because we see the value that transparency and significant savings provide to all relevant stakeholders,” said Cynthia Meiners, Strategic Program Development Officer at GoodRx. “We are excited to partner with Navitus to deliver lower-cost prescriptions to their members, and also strengthen the impact of our prescription savings within the insurance benefit marketplace.”.

GoodRx战略计划开发官员Cynthia Meiners说：“我们专注于扩大保险福利市场，因为我们看到透明度和大量储蓄为所有相关利益相关者提供的价值。“我们很高兴与Navitus合作，为其成员提供低成本的处方，并加强我们处方储蓄在保险福利市场中的影响。”。

No additional action is required by eligible Navitus members to access GoodRx savings through the Savings Connect program. Individuals simply show their existing Navitus benefit card at the pharmacy counter, and then GoodRx and Navitus automatically review and identify the best prescription cost available.

合格的Navitus成员无需采取额外行动，即可通过savings Connect计划获得GoodRx储蓄。个人只需在药房柜台显示他们现有的Navitus福利卡，然后GoodRx和Navitus自动查看并确定可用的最佳处方成本。

The amount paid by the member is applied to the deductible and out of pocket maximum. This process also leverages clinical data integration to ensure all claims remain associated with the member’s prescription record..

会员支付的金额适用于免赔额和自付额。此过程还利用临床数据集成来确保所有索赔均与会员的处方记录相关联。。

“Navitus strives to make medications more affordable for the people who need them. As healthcare costs rise, it is critical that we align with companies that share our mission to drive out needless costs for our members,” said David Fields, CEO of Navitus Health Solutions. “We are thrilled to be collaborating with GoodRx to deliver lower prices for our members while creating a seamless experience at the pharmacy.”.

Navitus公司首席执行官David Fields说：“Navitus致力于为需要他们的人提供更加实惠的药物，随着医疗保健成本的上升，我们必须与那些共同承担我们使命的公司保持一致，为我们的成员降低不必要的成本健康解决方案。“我们很高兴与GoodRx合作，为我们的成员提供更低的价格，同时在药房创造无缝体验。”。

Eligible Navitus members can already take advantage of the Savings Connect program on many commonly prescribed generic prescriptions at in-network pharmacies, with an accelerated rollout to additional clients expected in January 2024. This program was previously introduced to clients of EpiphanyRx, Navitus’ in-house solution for emerging and mid-market employer groups, in Q4 2022..

符合条件的Navitus成员已经可以利用网络药房中许多常用处方的Savings Connect计划，并有望在2024年1月加速推出其他客户。该计划之前于2022年第4季度推出给EpiphanyRx客户，Navitus为新兴和中等市场雇主团体提供内部解决方案。。

About GoodRx

关于GoodRx

GoodRx is a leading resource for healthcare savings and information that makes healthcare affordable and convenient for all Americans. We offer consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information.

GoodRx是医疗储蓄和信息的领先资源，使所有美国人都能负担得起医疗保健。我们为消费者提供透明和低价格的品牌和仿制药，通过远程医疗提供价格合理方便的医疗服务提供者咨询以及全面的医疗保健研究和信息。

Since 2011, we have helped consumers save over $60 billion and are one of the most downloaded medical apps over the past decade..

自2011年以来，我们帮助消费者节省了超过600亿美元，是过去十年中下载最多的医疗应用之一。。

GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts.

GoodRx定期在其投资者关系网站上发布对投资者可能重要的信息https://investors.goodrx.com.我们打算使用我们的网站作为披露材料非公开信息的手段，并遵守我们在FD法规下的披露义务。因此，鼓励投资者和潜在投资者定期咨询GoodRx的网站以获取重要信息，此外还要遵循GoodRx的新闻稿，向证券交易委员会（“SEC”）提交申请以及公开电话和网络广播。

The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release..

包含在GoodRx网站上或可以通过GoodRx网站访问的信息不是通过引用合并到本新闻稿中，也不是本新闻稿的一部分。。

About Navitus

关于Navitus

Navitus Health Solutions, LLC, owned by SSM Health and Costco Wholesale Corporation, was founded in 2003 as an alternative to traditional pharmacy benefit management (PBM) models. Navitus approaches pharmacy services differently. We are purpose-driven to help humans and committed to removing cost from the drug supply chain to make medications more affordable for the people who need them.

由SSM Health和Costco批发公司拥有的Navitus Health Solutions，LLC成立于2003年，是传统药房福利管理（PBM）模型的替代品。Navitus以不同的方式处理药房服务。我们的目标是帮助人类，并致力于从药物供应链中消除成本，使药物更适合需要它们的人。

We proudly serve over 11 million people through more than 1,000 plan sponsor and health plan client relationships. Our transparent, fully pass-through model enables clients to achieve their goals and drive desired health and financial outcomes. To learn more about Navitus, visit navitus.com..

我们自豪地通过1000多个计划发起人和健康计划客户关系为1100多万人服务。我们透明的，完全通过的模式使客户能够实现他们的目标，并推动理想的健康和财务成果。要了解更多关于Navitus的信息，请访问Navitus.com。。

GoodRx Forward-looking Statements

GoodRx前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding consumer savings; the demand and success of the Savings Connect program and the benefits to consumers and GoodRx from such offering; and GoodRx’s plans, expectations and objectives regarding the Savings Connect program and the insurance benefit market.

本新闻稿包含1995年“私人证券诉讼改革法”含义内的前瞻性声明。本新闻稿中包含的与历史事实事项无关的所有声明均应视为前瞻性声明，包括但不限于有关消费者储蓄的声明；储蓄连接计划的需求和成功以及此类产品对消费者和GoodRx的益处；以及GoodRx关于储蓄连接计划和保险福利市场的计划，期望和目标。

These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to changes in medication pricing which are significantly impacted by pricing structures negotiated by industry participants; GoodRx’s ability to achieve broad market education and change consumer purchasing habits; GoodRx’s reliance on a limited number of industry participants; risks related to government regulation of the internet, e-commerce, consumer data and privacy, information technology and cyber-security; and the important factors discussed in the sections entitled “Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year ended December 31, 2022, as updated by GoodRx’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, and GoodRx’s other filings with the SEC.

这些陈述既不是承诺也不是保证，但涉及已知和未知的风险，不确定性和其他可能导致实际结果，绩效或成就与前瞻性陈述所表达或暗示的任何未来结果，绩效或成就大不相同的重要因素，包括但不限于，与药物定价变化有关的风险受到行业参与者协商的定价结构的重大影响；GoodRx能够实现广泛的市场教育并改变消费者购买习惯；GoodRx依赖有限数量的行业参与者；与政府监管互联网，电子商务，消费者数据和隐私，信息技术和网络安全有关的风险；以及GoodRx在2022年12月31日结束的年度10-K表格年度报告中题为“风险因素”的章节中讨论的重要因素，由GoodRx在2023年6月30日结束的季度10-Q表格季度报告更新，以及GoodRx与SEC的其他文件。

These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release..

这些因素可能导致实际结果与本新闻稿中的前瞻性声明所表明的结果大不相同。。